Michael E. Bowdish, MD

• Assistant Professor of Surgery
• Division of Cardiothoracic Surgery
• University of North Carolina School of Medicine
• Chapel Hill, North Carolina

Histamine released by the mast cells promotes capillary leakage treatment of chronic pain guidelines ibuprofen 600 mg buy fast delivery, leading to airway edema pain management with shingles buy ibuprofen with a visa. These three leukotrienes marianjoy integrative pain treatment center purchase 400 mg ibuprofen with mastercard, called cysteinyl leukotrienes pain treatment goals ibuprofen 400 mg order with mastercard, are central to the pathophysiology o asthma because they induce marked bronchoconstriction pain treatment quotes 600 mg ibuprofen purchase fast delivery. Leukotriene D4 is 1,000 times more potent than histamine in producing bronchoconstriction. Leukotrienes also cause mucus hypersecretion, capillary leakage, and vasogenic edema and recruit additional inf ammatory cells. The e ect o the leukotrienes, though slower in onset, is more power ul and sustained than that o the pre ormed mediators. Mast cells also release tryptase, a protease that activates receptors on epithelial and endothelial cells, inducing the expression o adhesion molecules that attract eosinophils the major physiologic role o eosinophils is to de end against parasitic in ections. Once recruited to the airway, eosinophils have a complex, multi unctional role in asthma. Activated eosinophils secrete cytotoxic granules that cause local tissue damage and induce airway remodeling, lipid mediators and neuromodulators that a ect airway tone, and cytokines and chemokines that recruit other inf ammatory cells. Eosinophils also produce matrix metalloproteinases that contribute to airway remodeling. Eosinophils contribute both directly and indirectly to airway hyperresponsiveness. Eosinophil-derived cysteinyl leukotrienes and neuropeptides (such as substance P) increase vasodilation, vascular permeability, mucus hypersecretion, and airway smooth muscle contraction. Finally, eosinophils are immunomodulatory cells that can ampli y the immune response in asthma. Eosinophils up-regulate endothelial adhesion molecules and thereby recruit other inf ammatory cells. Eosinophils are also antigenpresenting cells capable o urther activating T lymphocytes. This distinction emphasizes the clinical uses o these agents and helps patients understand and adhere to the prescribed regimen. These cytokines cause acute airway inf ammation and produce acute asthmatic symptoms (an asthma "attack" or exacerbation). Together, the inf ammatory mediators and catabolic enzymes produced by eosinophils, mast cells, and neurons cause chronic airway inf ammation and lead to airway remodeling. In general, bronchodilators, which alleviate smooth muscle bronchoconstriction, are used as relievers, and anti-inflammatory medications, which decrease airway inflammation, are used as controllers. There is also evidence that some medications-methylxanthines, for example-have both bronchodilatory and antiinflammatory effects. Y used fluticasone (an inhaled corticosteroid) as a controller, with albuterol (a short-acting 2-agonist) as a reliever. Because sympathomimetics cause rapid relaxation o airway smooth muscle, 2-adrenergic agonists are particularly e ective in relieving acute asthma symptoms. Both systemic and aerosolized agents that stimulate 2-adrenergic receptors are e ective therapies or asthma. One early treatment or asthma involved the subcutaneous administration o adrenaline (epinephrine). By the middle o the twentieth century, epinephrine was made into an inhaled ormulation that is still available today. The nonselective adrenergic agonist ephedrine (Ma-Huang) has been used as a remedy or asthma or centuries by practitioners o traditional Chinese medicine. Epinephrine is a nonselective adrenergic agonist that binds to -, 1-, and 2-adrenergic receptors (see Chapter 11, Adrenergic Pharmacology). Although it is an e ective bronchodilator, epinephrine also causes cardiac stimulation via 1-receptors, leading to tachycardia, palpitations, and potentially arrhythmias, and peripheral vasoconstriction via -receptors, leading to hypertension. While epinephrine stimulates both - and -adrenergic receptors, isoproterenol stimulates only -adrenergic receptors. Isoproterenol stimulates both 1- and 2-receptors and there ore causes both bronchodilation and cardiac stimulation, but because it does not stimulate -receptors, it does not cause peripheral vasoconstriction. Isoproterenol is not used requently in current practice because o the availability o agents that are more selective or 2-receptors and the potential adverse cardiac e ects at higher doses o isoproterenol. Indeed, an epidemic o asthma-associated deaths in Great Britain in the mid-1960s was attributable to the use o highdose isoproterenol inhalers, possibly due to the combined e ect o hypoxemia rom asthma and cardiac stimulation rom isoproterenol. The f rst agents to o er relative 2 selectivity were isoetharine and metaproterenol, although both drugs had moderate 1 e ects. The newer drugs terbutaline, albuterol (also re erred to as salbutamol), pirbuterol, and bitolterol bind to 2-adrenergic receptors 200­400 times more strongly than to 1-receptors and cause signif cantly milder cardiac e ects than the less selective adrenergic agonists. Albuterol was the f rst o the strongly 2-selective agents to be available in inhaled orm, urther reducing systemic e ects. Modern inhaled 2-selective agonists were the f rst drugs to allow regular treatment o asthma with an acceptable adverse e ect prof le. Nonetheless, at high doses, especially i taken orally, even these drugs can cause cardiac stimulation and tachycardia. In addition, since 2-adrenergic receptors are expressed in peripheral skeletal muscle, activation o these receptors by 2-selective agents can result in a tremor. Albuterol is a racemic mixture o two stereoisomers: R-albuterol (or levalbuterol) and S-albuterol. Levalbuterol, which is available as a pure enantiomer, has tighter binding to 2-receptors and is more 2-selective. In contrast, the S isomer induces airway hyperresponsiveness in animal models, although in clinical practice, this e ect has not been signif cant. Leukotrienes are some o the most potent bronchoconstrictors known and are important mediators o inf ammation in the airway. Drugs that inhibit leukotriene production or leukotriene receptor binding have a role in asthma therapy. Leukotriene A4 is converted to leukotriene C4 by the action o leukotriene C4 synthase in mast cells and eosinophils, and leukotriene C4 is transported out o the cell. Leukotriene C4 is converted to leukotriene D4 and then to leukotriene E4; all three o these cysteinyl leukotrienes bind to CysL T1 receptors expressed on airway smooth muscle cells, leading to bronchoconstriction and airway edema. Leukotriene A4 is converted to leukotriene B4 by epoxide hydrolase in neutrophils and monocytes. The leukotriene pathway can be inhibited by the 5-lipoxygenase inhibitor zileuton or by the CysL T1 receptor antagonists montelukast and za rlukast. Bronchodilators Bronchodilators a ect airway smooth muscle tone by acting on autonomic nervous system receptors and signaling pathways. The combination o decreased intracellular calcium, increased membrane potassium conductance, and decreased myosin light chain phosphorylation leads to smooth muscle relaxation and bronchodilation. There is signi cant variability in clinical response among patients using 2-agonists. Some o this variability may be mediated through variants in the gene or the 2adrenergic receptor. Subjects homozygous or this genetic variant who receive regularly scheduled albuterol doses develop a decline in their peak expiratory f ow rate (a measure o bronchoconstriction), while subjects without the polymorphism develop increased peak f ow rates with scheduled albuterol use. Although the pharmacogenetics o the 2-adrenergic receptor are complicated and have yielded inconsistent associations, it is likely that some o the variability in drug response results rom genetic inf uences. Most 2-adrenergic agonists have a rapid onset o action (15 to 30 minutes), a peak e ect at 30 to 60 minutes, and a duration o action o approximately 4 to 6 hours. This time course o drug action makes the 2-agonists good candidates or use as asthma relievers (or rescue inhalers) during acute attacks. However, this pro le also makes the 2-agonists poor candidates or control o nocturnal asthma and or prevention o attacks, although they can be used prophylactically be ore exposure to a known trigger such as exercise. As such, these agents have a 12- to 24-hour duration o action, making them good candidates or prevention o bronchoconstriction. Although ormoterol and salmeterol are reasonable asthma controllers, these agents do not treat the underlying inf ammation. In act, regular use o ormoterol or salmeterol may be associated with an increase in asthma deaths. Because patients may eel better on long-acting -agonists, they may receive lower doses o inhaled corticosteroids or no inhaled corticosteroids at all. Since inhaled corticosteroids reduce the risk o asthma exacerbation (see below), the reduction or withdrawal o inhaled corticosteroids may place patients at increased risk o asthma hospitalization and atal asthma attack. Because salmeterol has a slower onset o action than albuterol, it should not be used or acute asthma f ares. Formoterol does have a rapid onset o action and can be used as a rescue inhaler, although it is not yet approved or this indication in the United States. One strategy has been to combine ormoterol with an inhaled corticosteroid (budesonide) or use as needed in patients with mild asthma. Every time the patient uses this combination, the ormoterol is available to provide acute relie o symptoms, and the patient also receives a dose o the inhaled corticosteroid to help quell the underlying inf ammation. Anticholinergics Anticholinergic agents were the rst medications used to treat asthma in Western medicine. To this day, asthma exacerbations that are not responsive to inhaled 2-adrenergic agonists, or where inhaled -agonists are contraindicated (such as in patients with cardiac ischemia or arrhythmia), can be treated with inhaled ipratropium bromide. Because inhaled atropine is highly absorbed across the respiratory epithelium, it causes many systemic anticholinergic e ects, including tachycardia, nausea, dry mouth, constipation, and urinary retention. Unlike atropine, ipratropium is not signi cantly absorbed, and these adverse systemic e ects are minimized. Nonetheless, inhaled ipratropium can cause dry mouth and gastrointestinal upset through its deposition in the mouth and inadvertent oral absorption, and i nebulized ipratropium is inadvertently delivered to the eye, it can produce mydriasis (pupillary dilation) and increase intraocular pressure, resulting in angle-closure glaucoma. Like ipratropium, these long-acting anticholinergic agents are quaternary ammonium salts that produce ew systemic e ects because they are not systemically absorbed upon inhalation. Moreover, aclidinium is hydrolyzed rapidly in plasma, urther reducing systematic exposure. Antimuscarinic agents are competitive antagonists at muscarinic acetylcholine receptors. O the our muscarinic receptor subtypes expressed in the lung (M1, M2, M3, and M4), the excitatory M3 receptor is the most important in mediating smooth muscle contraction and mucus gland secretion in the airway. Ipratropium and the long-acting anticholinergic agents antagonize the e ect o endogenous acetylcholine at M3 receptors, leading to bronchorelaxation and decreased mucus secretion. Tiotropium, umeclidinium, and aclidinium have a long duration o action, which enables once-daily dosing, largely because o their slow dissociation rom M3 receptors. In chronic asthma, cholinergic stimulation has only a secondary role in causing bronchoconstriction, although increased vagal stimulation at night may be an important contributor to nighttime symptoms. Methylxanthines and Phosphodiesterase Inhibitors Two methylxanthines, theophylline and aminophylline, are occasionally used in asthma treatment. The mechanism o action o these drugs is complex, but their primary bronchodilatory e ect appears to be due to nonspeci c inhibition o phosphodiesterase isoenzymes. By this mechanism, theophylline can control chronic asthma more e ectively than would be expected on the basis o its bronchodilatory e ect alone. Some o the adverse e ects o methylxanthines, including cardiac arrhythmias, nausea, and vomiting, are also mediated by phosphodiesterase inhibition, although the responsible isoenzymes remain to be elucidated. Theophylline is a structural relative o ca eine, di ering only by a single methyl group, and both ca eine and theophylline are adenosine receptor antagonists. Adenosine receptors are expressed on airway smooth muscle cells and mast cells, and antagonism o these receptors could play a role in preventing both bronchoconstriction and inf ammation. However, experiments with speci c adenosine receptor antagonists that do not inhibit phosphodiesterase have shown little bronchodilation, suggesting that phosphodiesterase inhibition is the primary mechanism o action o methylxanthines in asthma. Nonetheless, adenosine receptor antagonism is responsible or many secondary e ects o theophylline, including increased ventilation during hypoxia, improved endurance o diaphragmatic muscles, and decreased adenosine-stimulated mediator release rom mast cells. In addition, some adverse e ects o theophylline, such as tachycardia, psychomotor agitation, gastric acid secretion, and diuresis, are mediated through adenosine receptor antagonism. Because methylxanthines are nonselective and have multiple mechanisms o action, they cause multiple adverse e ects and have a relatively narrow therapeutic index. At supratherapeutic levels, theophylline produces nausea, diarrhea, vomiting, headache, irritability, and insomnia. At even higher doses, seizures, toxic encephalopathy, hyperthermia, brain damage, hyperglycemia, hypokalemia, hypotension, cardiac arrhythmias, and death can occur. For this reason, the role o theophylline in the treatment o chronic asthma has diminished. Theophylline is still used occasionally with routine monitoring o plasma drug levels when -adrenergic agonists and corticosteroids are ine ective or contraindicated. Magnesium Magnesium ions inhibit calcium transport into smooth muscle cells and can inter ere with intracellular phosphorylation reactions that induce smooth muscle contraction. For this reason, magnesium sul ate is commonly used as a tocolytic to inhibit uterine contraction and delay preterm labor. Magnesium has similar e ects on airway smooth muscle and has been used experimentally in acute asthma exacerbations. Although the results o clinical studies have been variable, two meta-analyses have suggested a bene t to using magnesium sul ate in patients with severe asthma exacerbations presenting to the emergency department. Magnesium was not used in the introductory case, but it would have been a reasonable therapeutic option at the time o Mr. Anti-Inf ammatory Agents As detailed above, allergic inf ammation o the airways orms the pathophysiologic basis or asthma. To control persistent asthma and prevent exacerbations o acute asthma, treatment o all but the mildest orms o the disease should generally include anti-inf ammatory agents. Corticosteroids have long been mainstays o asthma treatment, although the pro ound adverse e ects o systemically administered corticosteroids remained problematic until the development o inhaled ormulations. Three additional classes o drugs with anti-inf ammatory mechanisms o action are also used or the treatment o asthma: cromolyns, leukotriene pathway modi ers, and a humanized monoclonal anti-IgE antibody.

For alignment 1 allied pain treatment center inc cheap ibuprofen 600 mg online, there are two equivalent alignments where the effects of the adjacent protons cancel each other out and do not perturb the signal of the methyl group from its predicted shift (ca 1 pain treatment center of illinois new lenox purchase generic ibuprofen from india. This produces a triplet where the central line is twice the height/area of the two lines produced by alignments 2 and 3 pain medication for dogs with hip dysplasia ibuprofen 400 mg purchase line. The methyl group A appears cape fear pain treatment center pa purchase ibuprofen 400 mg otc, as it does in methyl acetate pain management for dying dog purchase ibuprofen 400 mg with visa, as a singlet since it is isolated from any adjacent protons. The effect of adjacent protons on the signal for a given group is known as coupling and coupling constants are given in Hz; the range of coupling constants between adjacent protons is 0­20 Hz. The coupling constant, J, is a measure of the interaction between a pair of protons. In a vicinal system of the general type Ha­C­C­Hb, then Jab is the coupling of Ha with Hb, which must be equal to the coupling of Hb with Ha, Jba, therefore Jab = Jba. Coupling resonances show a roof effect by which the relative binomial intensities of the peaks tend to lean toward the coupling partner. When two protons are close in chemical shift, coupling can cause their signals to overlap. The coupling constant is independent of the applied magnetic field, and thus the size of coupling constants in ppm will decrease with increasing field strength although their values in Hz remain the same. The higher the field strength, the less likely it is that signals from individual protons will overlap. In an aliphatic ring system, the magnitude of the J coupling is dictated by the torsion angle between the two coupling nuclei according to the Karplus equation (see Animation 8. Answers:1­doublet;2­triplet;3­singlet;4­doublet;5­quartet;6­multipletordoubletof septet Nuclear magnetic resonance spectroscopy Seeanswerhere 176. If the differences in coupling constants of adjacent protons are small, not widely different, the patterns tend to merge into those that would be expected if all the adjacent protons coupled identically. This is the case with propyl acetate, where coupling to five adjacent protons on two carbons produces six lines. In reality, coupling patterns are often more complex than the simple n+1 rule since the neighbouring protons are often not equivalent to each other. For a proton with two types of neighbours, the number of lines are L = (n1 + 1)(n2 + 1). However, a molecule can have more than one spin system, where groups of protons are separated by a heteroatom or atoms which are not substituted with a proton. Subscripts are applied for magnetically equivalent protons, and chemical equivalence is represented by primes. As the chemical shifts of two non-equivalent protons move closer together and thus approach the coupling constants line perturbation occurs, where the outside lines become smaller. These doublets exhibit shoulder peaks, indicating that the protons are magnetically non-equivalent due to the further meta and para (i) Nuclear magnetic resonance spectroscopy Seeanswerhere 182. The simple explanation is that the pairs A and A and B and B are not always equivalent, since at a given instant they may be affected differently by the protons they are interacting with. Such spectra are known as second-order spectra and can only be analysed accurately by using quantum mechanical calculations. Each proton is described as a doublet of doublets, since the two coupling constants are numerically different. It couples with Hb most strongly where the dihedral angle is 180° and less strongly to Ha where the dihedral angle is 60°. Protons Ha and Hb are close in chemical shift and, in addition to coupling to Hc, they also couple to each other strongly via geminal coupling. The close chemical shifts of these protons in combination with strong geminal coupling produce a strong line perturbation. A and B are close in chemical shift, but only weakly coupled via meta coupling and line perturbation, depends on the ratio of chemical shift difference to strength of coupling is minimal. Hb is further split by strong ortho-coupling to Hc, which has a chemical shift well upfield due to shielding by the ortho hydroxyl group. The coupling constants between all the protons are very similar and there is an absence of long-range coupling. Proton 1 is coupled to proton 2 and proton 4 is coupled to proton 3, thus causing the signals to appear as doublets. The aromatic region is more complex than that observed for paracetamol because the four aromatic protons are nonequivalent. H-1 is a doublet due to coupling to H-2; H-2 appears as a triplet due to overlap of two doublets caused by coupling to H-1 and H-3. Similarly, H-3 is a triplet due to coupling equally with H-2 and H-4, and H-4 is a doublet due to coupling with H-3. H-1 and H-3 and H-2 and H-4, which can occur in aromatic systems and can be up to 3 Hz. This proton is attached to a chiral centre and is coupled to the two adjacent protons B1 and B2, which are nonequivalent since they are immediately next to a chiral centre. Thus proton C has two different coupling constants to protons B1 and B2, and appears as a doublet of doublets. The most complex signal in the spectrum is due to protons B1 and B2, and this requires a more detailed explanation. The place to start with the analysis of the signal for the B protons in salbutamol is with signal C, which gives the couplings of the B1 and B2 protons with the proton on position C. It is possible to calculate these quite precisely, and the table is only an approximate guide. As can be seen, the J mod 13C spectrum of salbutamol is much simpler than its proton spectrum. A J mod spectrum is one of the modern equivalents of the 13C spectrum; it allows the number of protons attached to the carbon atoms to be known while at the same time removing the signal broadening due to the coupling between 13C and its attached protons. In two-dimensional experiments, both the x and the y axes have chemical shift scales, and the two-dimensional spectra are plotted as a grid like a map. Information is obtained from the spectra by looking at the peaks in the grid and matching them to the x and y axes. Lactose consists of two monosaccharides, -glucose and galactose with impurities in the form of the free sugars. A similar technique is employed in identifying the amino acids in a peptide structure. Amorecomplexexample the anti-haemorrhagic drug tranexamic acid when drawn in a two-dimensional representation may look as if all four protons on position 2 and all four protons on position 3 are equivalent. This introduces a number of additional couplings between the protons in the molecule, leading to an increased complexity of its spectrum. The place to start in this type of assignment is usually with the simplest signal, which in this case is due to the 4 protons, which only couple to the 4 protons. The 4 protons themselves present the most complex signal since they are separately coupled to the 4, 3a and 3e protons, producing 3 × 3 × 3 = 27 lines, which are not all seen because of the overlap of the signals. The signals due to 2e and 3e protons are narrower since they only experience one large germinal coupling to the axial proton attached to the same carbon. For example, a drug can be rapidly quantified by measuring suitable protons (often isolated methyl protons) against the intense singlet for the methyl groups in t-butanol. The amount of drug present can be calculated using the following formula for the methyl groups in t-butanol used as an internal standard (int. Thus the purity of a substance can be determined without a pure standard for it being available. The low amount of codeine present would be likely to make its quantitation inaccurate in the example shown, which was only scanned for a few minutes. Since its signal is close to the baseline, a longer scan would improve the signal: noise ratio, giving better quantitative accuracy. The data obtained from the analysis is as follows: Stated content/tablet = aspirin 250 mg, paracetamol 250 mg, codeine phosphate 6. The resonance for each component decays at different diffusion rates by varying the gradient strength. The method practically allows non-destructive separation of the different components in an extract without using chromatography. The Y axis exhibits the diffusion coefficient of each component and the signals belonging to the two components in this simple mixture are linked to a diffusion coefficient and can be summed to give a concentration of each of the drug in the sample mixture. Para-aminophenol is a smaller molecule than paracetamol and thus has a higher diffusion coefficient. Resolution for data sets from mixtures of more than five components can be analysed by employing a single channel method which only utilises a limited or smaller sweep width. In dereplication studies, there is a need to do rapid but sensitive spectral acquisitions where more precise data can be obtained at a shorter period of time without using up the sample. In classical mass spectrometry there was only one method of producing the charged molecules but now there are quite a number of alternatives. The drug was introduced into the mass spectrometer in a mobile phase containing methanol. If there is an electronegative atom in the molecule, such as oxygen or nitrogen, usually the positivechargeislocatedthere. The sample solution is mixed with matrix solution on a metal plate and allowed to dry prior to being introduced into the instrument. The calibration of the instrument drifts with time, and calibration has to be carried out regularly. Tuning should be carried out on a minimum of three ions covering the mass range of Mass spectrometry interest. The ring fragmentation shown above is found in the mass spectra of some drugswhichhavenitrogen-containingrings. The structures do not have to be exact, but it is possible to get close to the structure by breaking the appropriate bond. An advantage of ion trap instruments is that repeat fragmentation can be carried out. Thechromatogramwasobtained by using high-resolution Fourier transform mass spectrometry. Thus,variations in protein structure, such as degree of glycosylation, or in the terminal aminoacidsoftheprotein,canbeseenquiteclearly. In order to derive more structural information it is necessary to break the proteinintosmallpeptideunits. Oncethesequencesof the mixture of peptides derived from a protein are established, they can be matched against a database in order to try to identify the protein or at least relate it closely to a known protein. Practical Organic Mass Spectrometry: A Guide for Chemical and Biochemical Analysis. Answer: Y4, Y3, Y2, Y1, immonium ion for methionine Mass spectrometry See answer here 246. An understanding of the parameters which govern chromatographic performance has given rise to improvements in chromatography systems, so the ability to achieve high-resolution separations is continually increasing. The system suitability tests which are described at the end of this chapter are now routinely included in chromatographic software packages so that the chromatographic performance of a system can be monitored routinely. If a compound does not partition appreciably into the stationary phase, it will travel through the column at the same rate as the solvent. The length of time it takes an unretarded molecule to flow through the column is determined by the void volume of the column (Vo). Thus, in theory, it should take solvent or unretarded molecules, flowing at a rate of 1 ml/min, ca 1. This is a simplification of the actual process, but it provides a readily understandable model. Injection t0 solvent front or unretained component W1/2 h/2 Wb Time (min) assessed from the width of the peak at half its height W1/2 and its retention time using Equation 1: n = 5. Column efficiency is usually expressed in theoretical plates per metre: n ×100 L where L is the column length in cm. A stricter measure of column efficiency, especially if the retention time of the analyte is short, is given by Equation 2: N eff = 5. The longer an analyte takes to travel through a column, the more the individual molecules making up the sample spread out and the broader the band becomes. Detailed mathematical modelling of the processes leading to band broadening is very complex. The causes of band broadening can be formalised in the Van Deemter equation (Equation 3) as applied to liquid chromatography: H= A B + + C s u + Cm u1 2 1 + Cm u1 2 u [Equation3] H is the measure of the efficiency of the column (discussed above); the smaller the term, the more efficient the column. In liquid chromatography the eddy diffusion term also contains a contribution from streaming within the solvent volume itself, i. A (see the Cm term) is reduced if the diffusion coefficient of the molecule within the mobile phase is low because molecules take less erratic paths through not being able to diffuse out of the mainstream so easily. Y Solvent flow Particles of stationary phase B is the rate of diffusion of the molecule in the liquid phase, which contributes to peak broadening through diffusion either with or against the flow of mobile phase; the contribution of this term is very small in liquid chromatography. Its contribution to band broadening decreases as flow rate increases, and it only becomes significant at very low flow rates. Cs is the resistance to mass transfer of a molecule in the stationary phase and is dependent on its diffusion coefficient in the stationary phase and upon the thickness of the stationary phase coated onto silica gel: Cs = d 2 thickness Ds where d2 thickness is the square of the stationary-phase film thickness and Ds is the diffusion coefficient of the analyte in the stationary phase. Y Solid support Stationary phase Obviously the thinner and more uniform the stationary-phase coating, the smaller the contribution to band broadening from this term. It could be argued that this effect evens out throughout the length of the column, but in practice the number of random partitionings during the time required for elution is not sufficient to eliminate it. Cm is resistance to mass transfer brought about by the diameter and shape of the particles of the stationary phase and the rate of diffusion of a molecule in the mobile phase. Cm = d 2 packing Dm where d2 packing is the square of the stationary-phase particle diameter and Dm is the diffusion coefficient of the analyte in the mobile phase.

However blue sky pain treatment center/health services generic ibuprofen 400 mg free shipping, other prophylactic agents are signi cantly more e ective pain treatment center baton rouge louisiana 400 mg ibuprofen order free shipping, and this combination is not recommended knee pain treatment without surgery order ibuprofen overnight delivery. Proguanil may be used in a synergistic combination with atovaquone or both treatment and prevention o malaria (discussed above) pain treatment during pregnancy order 600 mg ibuprofen overnight delivery. Proguanil is usually well tolerated pain treatment in acute pancreatitis generic 600 mg ibuprofen mastercard, but it has been associated with oral ulcerations, pancytopenia, thrombocytopenia, and granulocytopenia. Antimalarial Drug Resistance Antimalarial drug resistance is a major public health problem and a signi cant barrier to the e ective treatment o individuals with malaria. Chloroquine was the standard therapy or treating individuals with malaria or many years a ter its introduction in 1946. Resistance was rst reported in the 1950s and steadily increased since then; at present, resistance has been reported everywhere in the world except on the island o Hispaniola and in ocal parts o Central America, South America, and Asia. Childhood mortality doubled in eastern and southern A rica in the 1980s and 1990s as chloroquine and sul adoxine­pyrimethamine resistance increased; chloroquine resistance was associated with an overall doubling o childhood mortality rom malaria during this period, with increases as high as 11- old in certain areas. Resistance to sul adoxine­pyrimethamine was reported a ter the combination was introduced in 1971 as a second-line therapy or treating individuals with chloroquine-resistant P. Resistance to sul adoxine­ pyrimethamine was initially reported in Southeast Asia but is now relatively widespread in South America and prevalent in A rica as well. Mef oquine resistance has not spread more widely as yet, in large measure due to the act that the drug is not now routinely used to treat individuals with malaria. Many actors contribute to the development o drug resistance by malaria parasites, including inappropriate and/or unsupervised drug use, inconsistent drug availability, poor adherence to treatment regimens due to adverse e ects and other actors, inconsistent quality o drug manu acturing, presence o counter eit drugs, and prohibitive drug costs. Five percent to 10% o individuals who live in poverty in the developing world have serologic evidence o previous E. Trophozoites typically multiply superf cial to the muscularis mucosae o the intestines and spread laterally. They may also penetrate more deeply, occasionally per orating the intestinal wall and spreading locally. Inside the human body, the trophozoites move using pseudopods and ingest bacteria, other protozoa, and host red blood cells. Symptoms due to amebiasis vary rom diarrhea and abdominal cramps to ulminant dysentery and hepatic abscess ormation. Fewer than 40% o individuals with amebic dysentery develop ever, and microscopic evaluation o the stool typically discloses ew neutrophils. The onset o symptoms can range rom a ew days to a year a ter exposure, or symptoms may never occur. Fermentation Pathways Life Cycle of Entamoeba histolytica Colonic in ection with E. Whether intestinal invasion occurs may be a unction o the number o cysts ingested, the strain o the parasite, the motility o the host gastrointestinal tract, and the presence o appropriate enteric bacteria to E. Ameba also lack enzymes o oxidative phosphorylation, the Krebs cycle, and pyruvate dehydrogenase. Instead, ameba (and many anaerobic organisms) utilize novel enzymes to provide a source or the electron trans ers that drive metabolism. Ingestion of Entamoeba histolytica cysts can result in several different clinical outcomes, ranging from asymptomatic excretion of the cysts to invasive disease. Asymptomatic infection occurs when the ingested cysts excyst (mature) in the small intestine but do not invade the intestinal mucosa. Invasive disease results when active trophozoites invade the intestinal epithelium. This invasion can result in asymptomatic colonization, intestinal amebiasis (amebic dysentery)- which is characterized by diarrhea and abdominal cramps-or intestinal perforation. This activity is in contrast to that o heme and cytochromes, which use iron centers to trans er electrons under oxidizing (aerobic) conditions. Indeed, phylogenetic analyses suggest that most o the genes encoding parasite ermentation enzymes, and many o the genes encoding parasite enzymes involved in core energy metabolism, have been laterally trans erred rom anaerobic bacteria. Although lateral gene trans er is extraordinarily requent between bacteria, it microbial cells that possess a large negative redox potential; such redox potentials are present in many anaerobic or microaerophilic luminal parasites. However, in poorly oxygenated tissues such as abscesses, metronidazole can be activated. The widespread use o metronidazole has led to drug resistance in Helicobacter pylori, a common bacterial cause o gastritis and peptic ulcers (see Chapter 47, Integrative Inf ammation Pharmacology: Peptic Ulcer Disease). Metronidazole resistance among luminal parasites has not yet become clinically important, however. There are three explanations or the slow development o resistance to metronidazole among luminal parasites. First, luminal parasites are generally diploid, so a single mutation will not typically con er resistance. Adverse e ects o metronidazole include gastrointestinal discom ort, headaches, occasional neuropathy, a metallic taste, and nausea. Metronidazole also causes nausea and f ushing when taken concomitantly with alcohol (a socalled disul ram-like e ect, caused by inhibition o ethanol metabolism). There ore, individuals with invasive amebiasis are typically treated rst with metronidazole (to eradicate trophozoites that are actively invading human tissue) and then with a second agent that has more intraluminal activity, such as iodoquinol or paromomycin. The latter two agents kill ameba by unknown mechanisms but are poorly absorbed rom the gastrointestinal tract and there ore reach high concentrations in the lumen o the colon. Fermentation enzymes of anaerobic organisms and mechanisms of metronidazole activation. Metronidazole is a prodrug; it contains a nitro group that must be reduced for the drug to become active. Two aspects of anaerobic metabolism provide opportunities for selective reduction of the nitro group. Tinidazole Tinidazole, a second-generation nitroimidazole related to metronidazole, is also e ective against a number o protozoa and is licensed or the treatment o giardiasis, amebiasis, and vaginal trichomoniasis. Its mechanism o action is unclear but is believed to be similar to that o metronidazole and related to the generation o cytotoxic ree radicals. Tinidazole is also better tolerated than metronidazole, but it is similarly ine ective as a luminicidal agent or the treatment o ameba in ections. Tinidazole is not recommended or use during the f rst trimester o pregnancy, during breasteeding, and in children less than 3 years o age. Nitazoxanide Nitazoxanide is a nitrothiazolyl-salicylamide derivative structurally related to metronidazole. Nitazoxanide has a broad spectrum o action, including activity against protozoa, anaerobic bacteria, and helminths. It is approved in the United States or use in children with giardiasis and in adults and children with cryptosporidiosis. A ter oral administration, nitazoxanide is rapidly hydrolyzed to the active metabolite tizoxanide. Other Antiprotozoal Agents Pentamidine can be used to treat early-stage A rican try- panosomiasis (A rican sleeping sickness), which is caused by Trypanosoma brucei gambiense and certain strains o T. Some strains o Trypanosoma have a high-a f nity uptake system or the drug, contributing to its selectivity. Pentamidine can cause atigue, dizziness, hypotension, pancreatitis, and kidney damage. Pentamidine is now used most commonly as a third- or ourth-line treatment or individuals with Pneumocystis jiroveci (P. Suramin interacts with many macromolecules and inhibits numerous enzymes, including those involved in energy metabolism. Melarsoprol was developed by conjugating the heavy metal chelator dimercaptopropanol to the trivalent arsenic o melarsen oxide. Melarsoprol also inhibits the uptake o adenine and adenosine by trypanosomal transporters. Mammalian cells are less permeable to the drug than are trypanosomes, and the drug has some selectivity on this basis. In addition, 5­10% o individuals with latestage A rican trypanosomiasis develop intense inf ammation o the brain a ter administration o melarsoprol (reactive encephalopathy); this complication is associated with a mortality rate o greater than 50%. Concomitant administration o corticosteroids lessens the likelihood o reactive encephalopathy. Polyneuropathy a ter melarsoprol administration is also common (10%) and can be lessened by concomitant administration o thiamine. Ef ornithine is highly e ective against both early- and late-stage West A rican sleeping sickness but not against East A rican trypanosomiasis (caused by T. Ef ornithine is a selective and irreversible inhibitor o ornithine decarboxylase and thus o polyamine synthesis. Ornithine decarboxylase converts ornithine to putrescine; this is a rate-limiting step in the synthesis o putrescine and the polyamines spermine and spermidine. Polyamines are involved in nucleic acid synthesis and the regulation o protein synthesis. The drug undergoes reduction and generates toxic intracellular oxygen radicals in the parasite. These radicals can then be reoxidized and, in the process, generate superoxide anions, which react with water to produce cytotoxic hydrogen peroxide. Some parasites, such as trypanosomes, lack catalase and other enzymes capable o degrading hydrogen peroxide. Mammalian cells are protected because o their complement o antioxidant enzymes such as catalase, glutathione peroxidase, and superoxide dismutase. Ni urtimox can cause anorexia, vomiting, memory loss, sleep disorders, and seizures. Sodium stibogluconate and meglumine antimonate are used to treat leishmaniasis, which is caused by parasites o the genus Leishmania. It is postulated that these drugs inhibit the glycolytic pathway and atty acid oxidation, processes that are crucial or intermediary metabolism. Resistance o Leishmania to antimonial agents is being recognized with increasing requency, especially in South Asia. It is a synthetic ether phospholipid analogue that is chemically similar to natural phospholipids present in cell membranes. Milte osine has been shown to have antineoplastic, immunomodulatory, and antiprotozoal activity. It is presumed that the cytostatic and cytotoxic e ects o milte osine are caused by inhibition o enzyme systems associated with plasma membranes (such as protein kinase C) and inhibition o phosphatidylcholine biosynthesis. Milte osine may also inhibit platelet activating actor-induced responses and inositol phosphate ormation. Parasitic helminths can in ect the liver, blood, intestines, and other tissues in human hosts. Clinically signi cant worms can be divided phylogenetically into three classes: nematodes (roundworms), trematodes (f ukes), and cestodes (tapeworms). The physiology o Onchocerca volvulus, which causes onchocerciasis ("river blindness"), provides an example o potential targets or antihelminthic drugs. Although the majority o the ollowing discussion ocuses on the physiology and pharmacology o onchocerciasis, several other antihelminthic agents are also presented. Physiology o Helminths Humans can become in ected with helminths when they ingest ood or water contaminated with eggs or larvae. In addition, larvae in soil can penetrate human skin, and insects can transmit still other larvae through bites. During the sexual stage, adult worms release additional eggs or larvae, which can then pass out o the host through the gastrointestinal or urinary tracts. In the environment or within vector hosts, eggs or larvae then become inective or humans, and the cycles start over. S tra tum corne um Epide rmis De rmis Life Cycle of Onchocerca volvulus Adult fila ria Onchocerciasis is one o eight human larial in ections (a speci c type o nematodal worm in ection). Adult worms are large (3­80 cm in length), look like angel-hair pasta, and can live or 10­15 years. The nodules have a characteristic appearance that was recognized by the pathologist. From these nodules (onchocercomata), gravid emales release millions o micro lariae, which migrate reely through the skin and cornea. I ingested by a Simulium f y, additional maturation can occur, and the cycle can continue. The diagnosis o onchocerciasis is usually based on microscopic detection o micro lariae in skin snips, not on pathological examination o excised onchocercomata. Micro lariae are small (200­400 m); as they degenerate and die, they cause local inf ammatory reactions, provoking itching, dermatitis, and, eventually, scarring. When micro lariae die in the cornea, they induce a punctate keratitis that, over years, leads to scarring and blindness. Such ocular involvement made onchocerciasis a leading cause o in ectious blindness in the world (along with trachoma) and is the reason onchocerciasis is also re erred to as "river blindness" (also ref ecting the act that the blackf ies carrying the larvae inhabit areas with f owing streams, such as the one in which Thumbi enjoyed shing). Without treatment, Thumbi could well become one o the thousands o individuals in the world who are currently blind or visually impaired rom onchocerciasis. The motor neurons o invertebrates are unmyelinated, making them more vulnerable to neurotoxins than the myelinated somatic motor neurons o humans. Adult f larial worms mate in subcutaneous nodules in humans, releasing microf lariae that migrate through the skin and subcutaneous tissues and cause dermatitis and pruritus as they die. Microf lariae that die in the cornea induce ocular in ammation, which can lead to corneal scarring and blindness ("river blindness"). Ivermectin, the agent o choice or treating individuals with onchocerciasis, is e ective only against microf lariae; the drug does not kill adult f larial worms. Pharmacology of Antihelminthic Agents Agents That Interrupt Neuromuscular Activity Ivermectin Ivermectin is a semisynthetic macrocyclic lactone that acts against a broad range o helminths and arthropods and that has been used most extensively to treat and control onchocerciasis. This results in hyperpolarization o neuromuscular cells and causes pharyngeal paralysis.

Ibuprofen 600 mg order line. Pancreatic Cancer: A Beautiful Story of Survival.

Patients with neuropsychiatric disease pain neck treatment order genuine ibuprofen on-line, alcoholism chronic pain syndrome treatment guidelines discount generic ibuprofen canada, and chronic kidney disease should avoid the drug pain management in dogs and cats purchase ibuprofen cheap. Alcohol pain treatment for bladder infection order ibuprofen 600 mg fast delivery, isoniazid advanced pain treatment center jackson tn generic ibuprofen 600 mg overnight delivery, and ethionamide potentiate its toxicity; pyridoxine may mitigate cycloserine-induced peripheral neuropathy. Cycloserine is a structural analogue of D-alanine that inhibits the racemic interconversion of L-alanine to D-alanine by alanine racemase. Telavancin, dalbavancin, and oritavancin are related lipoglycopeptides with a similar spectrum o action. These agents interrupt cell wall synthesis by binding tightly to the D-Ala-D-Ala terminus o the murein monomer unit, inhibiting peptidoglycan polymerization and thereby blocking the addition o murein units to the growing polymer chain. Telavancin and oritavancin have, in addition to the D-Ala-D-Ala-binding moiety, a lipid side chain that interacts with the bacterial cell membrane; this lipid anchor both enhances drug binding to the D-Ala-D-Ala terminus and e ects depolarization o the bacterial membrane, resulting in higher antibacterial potency than vancomycin. In addition, the lack o an acetylglucosamine group in dalbavancin allows or increased activity against resistant enterococci. The addition o an N-alkyl-p-chlorophenylbenzyl substituent on the disaccharide sugar results in increased activity against enterococci, including vancomycin-resistant strains. Dalbavancin and oritavancin have prolonged elimination hal lives, allowing or once-weekly dosing. Oral vancomycin is commonly used to treat gastrointestinal in ections caused by C. The adverse e ects o vancomycin include skin ushing or rash-the so-called red man syndrome -which is due to release o histamine and can be avoided by decreasing the rate o intravenous in usion or preadministering antihistamines. Patients with underlying renal dys unction need adjusted dosing and measurement o drug levels in order to mitigate nephrotoxicity. Telavancin appears to have a toxicity prof le similar to that o vancomycin, with a slightly lower risk o in usion-related reactions but a higher incidence o nephrotoxicity. Dalbavancin does not appear to cause inusion-related reactions or nephrotoxicity; the most common adverse event in clinical trials was mild gastrointestinal upset. Oritavancin has similar toxicities to vancomycin except or a much lower risk o renal toxicity. In order to minimize this inter erence, blood drawn or these assays should be taken near the time o the trough plasma concentration o telavancin or oritavancin. As with D-AlaD-Ala, D-Ala-D-lactate is incorporated into the murein monomer unit and participates readily in the transpeptidase reaction, but the D-Ala-D-lactate dipeptide is not bound by vancomycin and related glycopeptides. Two enzymes mediate the synthesis o D-Ala-D-lactate: VanH, a dehydrogenase that generates D-lactate rom pyruvate, and VanA, a ligase that links D-Ala to D-lactate. VanH and VanA are encoded on a transposable element that can be ound on either the bacterial chromosome or an extrachromosomal plasmid. Dalbavancin and oritavancin are more stable than vancomycin and telavancin against the development o resistance to Staphylococcus and Streptococcus species. Oritavancin may be active against Enterococcus strains that exhibit resistance to the other glycopeptides. The -lactam family members (penicillins, cephalosporins, monobactams, and carbapenems) differ from one another in their backbone structures; individual drugs within these subclasses also differ in their R groups. Note the four-membered -lactam ring that is common to all four families (blue boxes); it is this ring that gives the agents their ability to block the transpeptidation reaction (and also their name). Bacteria expressing -lactamases are able to cleave the -lactam bond (blue line) that is required for antibiotic action. The -lactamase inhibitors clavulanic acid, sulbactam, and avibactam act as decoys by binding to (and thereby inhibiting) -lactamase enzymes. Note the structural similarity between the -lactamase inhibitors and the -lactam antibiotics. Inhibitors of Polymer Cross-Linking With more than 30 di erent agents currently in use, including the original penicillin and the dicloxacillin used in the introductory case, the -lactams are the largest and most widely prescribed class o antibiotics that inhibit bacterial cell wall synthesis. This ring makes every -lactam a structural analogue o the terminal D-Ala-D-Ala dipeptide o the Park nucleotide and hence a substrate or one or more bacterial transpeptidases. As with the Park nucleotide, the -lactam reacts covalently with the active-site serine in the transpeptidase, thereby orming an acyl enzyme intermediate. Unlike the Park nucleotide in the normal substrate reaction, however, the -lactam ring renders the carboxy terminal end o the -lactam unable to be cleaved rom the rest o the molecule. Recall that spectrum o action re ers to the number and variety o bacterial species against which an antibiotic shows bactericidal or bacteriostatic activity. Hence, broad-spectrum -lactams are typically active against Gram-negative as well as Gram-positive bacteria, whereas narrow-spectrum lactams are typically e ective only against Gram-positive organisms. Bacterial transpeptidases are located in the periplasmic space between the cytoplasmic membrane and the cell wall. Hence, to exert their e ects, -lactams must traverse the cell wall and, in the case o Gram-negative bacteria, the outer membrane as well. Both hydrophilic and (to a lesser extent) hydrophobic agents di use through the thick murein layer o Gram-positive bacteria, but hydrophilic agents pass through the outer membrane pores o Gram-negative bacteria much more readily than do hydrophobic agents. As a result, hydrophilic agents such as ampicillin, amoxicillin, and, especially, piperacillin and ticarcillin tend to have broad spectra o action, whereas hydrophobic agents such as oxacillin, cloxacillin, dicloxacillin, nafcillin, methicillin, and penicillin G tend to have narrow spectra o action (see discussion below or details). This means that some Gram-negative bacteria are inherently resistant to narrow-spectrum -lactams simply by virtue o the permeability barrier presented by their outer membrane. As noted above, bacteria typically have several transpeptidase enzymes that di er subtly in their substrate specif city and cross-linking activity; these di erences are especially prominent between rods and cocci. Most lactams have selectivity or several di erent transpeptidases; others, such as the penicillin analogue methicillin that was previously used against S. Antibiotic resistance can be encoded by either chromosomal (intrinsic) or acquired (extrinsic) genes. As their name implies, -lactamases are enzymes that inactivate -lactams via (hydrolytic) cleavage o the -lactam ring. More than 100 di erent -lactamases have been identif ed, each with activity against a particular -lactam or set o -lactams. Gram-negative bacteria produce much less -lactamase than Gram-positive bacteria do, but because the Gram-negatives concentrate the -lactamase where it is needed in the periplasmic space, the -lactamase is more e ective at con erring resistance. This concentration e ect, coupled with the strong permeability barrier to penicillins a orded by the bacterial outer membrane, makes Gram-negative bacteria largely re ractory to penicillin therapy. Because plasmids are easily trans erred by conjugation rom one bacterium to another, the resistance con erred by the plasmid can sweep rapidly through a bacterial population. Moreover, plasmids can "jump strains," spreading resistance rom one strain to another. Other bacteria, such as Enterobacter species, may overexpress a chromosomally encoded -lactamase that produces similarly broad resistance to -lactams. First, as noted above, new amilies o -lactams have been developed with structures that make them less susceptible to cleavage by existing -lactamases. Second, -lactamase inhibitors have been developed that can be co-administered with -lactam antibiotics. Avibactam is a novel -lactamase inhibitor recently developed or use in combination with ce tazidime to provide enhanced activity against resistant Gram-negative bacteria. To access the cytoplasm, aminoglycosides must di use passively across the cell wall be ore being transported actively across the cytoplasmic membrane. This new antigenic determinant can be recognized as "nonsel " by antibodies o the host immune system. Because -lactams increase cell wall permeability, co-administration o a -lactam acilitates the uptake o an aminoglycoside and thus enhances its e ect. As small molecules, -lactams would not be expected to stimulate immune responses by themselves, and indeed they do not. The most serious o these reactions is anaphylaxis, which typically occurs within an hour o drug administration and leads to bronchospasm, angioedema, and/or cardiovascular collapse. Proteins on the sur ace o red blood cells can also be modif ed by penicillin, leading to drug-induced autoimmune hemolytic anemia. Patients with a penicillin allergy should not receive ampicillin or other penicillins due to the high risk o cross-reactivity. Patients with a penicillin allergy other than serum sickness or anaphylaxis generally may receive a cephalosporin or a carbapenem. Aztreonam (a monobactam) is unique in that it has no cross-reactivity with either penicillins or carbapenems; however, cross-reactivity between aztreonam and ce tazidime (a cephalosporin), presumably due to a shared side chain, has been reported. Although allergic reactions to carbapenems can occur in patients with penicillin allergy, they are rare. The f rst o these subclasses, the penicillins, can be urther divided into f ve groups according to their spectra o action. The f rst group o penicillins includes penicillin G, which is intravenously administered, and penicillin V, its gastric acid-stable oral counterpart. Penicillin V is used to treat dental in ections and to prevent recurrent rheumatic ever in patients with a prior episode and recurrent streptococcal cellulitis in patients with lymphedema. Penicillin G is used to treat serious in ections with Gram-positive bacteria such as pneumococcus and S. High-dose penicillin G may cause seizures, in addition to the already mentioned hypersensitivity reactions and rash. Drug­drug interactions are rare, but the anticoagulant e ects o war arin may be potentiated by concomitant penicillin administration. The second group consists o the antistaphylococcal penicillins, including oxacillin, cloxacillin, dicloxacillin, nafcillin, and methicillin. These drugs are structurally resistant to staphylococcal -lactamase, which is encoded by plasmid genes in most clinical isolates. Because o their relative hydrophobicity, however, antistaphylococcal penicillins lack activity against Gram-negative bacteria. Intravenous antistaphylococcal penicillins are predominantly used or more serious methicillin-sensitive S. Use o the oral antistaphylococcal penicillins (cloxacillin and dicloxacillin) is somewhat limited by their gastrointestinal adverse e ects (nausea and antibioticassociated diarrhea) and occasionally by secondary development o C. Adverse e ects o intravenous na cillin include phlebitis at the injection site; agranulocytosis and acute interstitial nephritis occur at a higher rate than with the other penicillins. Oxacillin can cause hepatotoxicity, which is reversible with discontinuation o the drug. This positive charge enhances di usion through porin channels but does not con er resistance to -lactamases. These agents are e ective against a variety o Gram-positive cocci, Gram-negative cocci such as Neisseria gonorrhoeae and N. Intravenous ampicillin is used most commonly to treat invasive enterococcal in ections and Listeria meningitis; oral amoxicillin is used to treat uncomplicated ear, nose, and throat in ections, to prevent endocarditis in high-risk patients undergoing dental work, and as a component o combination therapy or Helicobacter pylori in ection. Agents in the ourth group o penicillins, the carboxy penicillins, are also broad in spectrum. The carboxyl group on the R side chain provides a negative charge that con ers resistance to some -lactamases but is less e ective than a positively charged amino group in acilitating di usion through porin channels. Resistance to the chromosomally encoded -lactamases o Enterobacter and Pseudomonas adds these organisms to the spectrum o the carboxy penicillins. This drug has both positive and negative charges on the R side chain and is generally more potent than the carboxy penicillins. Its spectrum o action is similar to that o the carboxy penicillins; in addition, ureido penicillins have activity against Klebsiella and enterococci. Piperacillin is currently available only in combination with the -lactamase inhibitor tazobactam. First-generation cephalosporins (cefazolin, cephalexin, and cefadroxil) are active against Gram-positive species as well as the Gram-negative rods Proteus mirabilis and E. These agents are sensitive to many -lactamases but are not degraded by the chromosomally encoded -lactamase o K. Cephalexin and ce adroxil are both administered orally and are used to treat skin and so t tissue in ections and streptococcal pharyngitis. In general, second-generation cephalosporins are resistant to more -lactamases than are f rst-generation cephalosporins. Thus, ce uroxime can be used to treat community-acquired pneumonia, and ce otetan is used to treat intra-abdominal and pelvic in ections, including pelvic in ammatory disease. Adverse e ects o these agents include diarrhea, mild liver enzyme elevation, and hypersensitivity reactions; rarely, agranulocytosis or interstitial nephritis can occur. Third-generation cephalosporins (ceftriaxone, cefotaxime, and cefpodoxime) are resistant to many -lactamases and are thus highly active against Enterobacteriaceae (E. The third-generation cephalosporins are less active against Gram-positive organisms than are the f rst-generation drugs; despite that, they have good activity against penicillin-intermediate S. Common uses include treatment o pneumonia, community-acquired meningitis due to S. In addition to the adverse e ects already mentioned, ce triaxone can cause cholestatic hepatitis, albeit uncommonly. Ceftazidime is another commonly used third-generation cephalosporin; its spectrum di ers rom the other agents in that it has signif cant activity against Pseudomonas aeruginosa and minimal activity against Gram-positive organisms. It is used predominantly to treat hospital-acquired Gram-negative bacterial in ections and documented in ections with P. Gram-negative bacteria that have acquired extended-spectrum -lactamase activity are resistant to third-generation cephalosporins. Ce epime is also more resistant to the chromosomally encoded -lactamases o Enterobacter than are third-generation cephalosporins. An uncommon adverse e ect is the development o autoantibodies against red blood cell antigens, typically without signif cant hemolysis. In addition, ce epime can in requently cause neurotoxicity including myoclonus and encephalopathy, particularly in the elderly and in patients with impaired renal unction; or the latter patients, the antibiotic requires dose adjustment. This drug is distinct in having antimicrobial activity against multidrug-resistant S. Ce taroline is only available intravenously and is approved or treatment o community-acquired pneumonia and skin in ections. Ceftolozane is a novel intravenous cephalosporin currently available in combination with the -lactamase inhibitor tazobactam. Ce tolozane is structurally similar to ce tazidime but has a more heavily substituted pyrazole at the 3-position side chain that con ers greater stability against -lactamase-producing Pseudomonas aeruginosa compared to ce tazidime.

Each tubulin subunit is a heterodimer composed of -tubulin (shades of purple) and -tubulin (shades of blue) pain medication for shingles ibuprofen 400 mg buy low cost. Microtubules are dynamic structures that grow and shrink lengthwise; the cylindrical tubes are composed of 13 subunits arranged concentrically pain treatment for lupus buy ibuprofen 400 mg, resulting in a diameter of 24 nm nice guidelines treatment back pain generic ibuprofen 400 mg buy on-line. One end of a microtubule is limited by -tubulin and is referred to as the (minus) end; the opposite end is limited by -tubulin and is referred to as the (plus) end pain evaluation and treatment center tulsa ok purchase ibuprofen 400 mg. The ability o microtubules to assemble and disassemble rapidly is important or their many physiologic roles pain medication for dogs uk buy ibuprofen 600 mg fast delivery. Pharmacologic agents can disrupt microtubule unction either by preventing the assembly o tubulin into microtubules or by stabilizing existing microtubules (and thereby preventing microtubule disassembly). Microtubules have important physiologic roles in mitosis, intracellular protein tra f cking, vesicular movement, and cell structure and shape. Mitosis is the physiologic role that is targeted pharmacologically; the other physiologic roles, however, predict many o the adverse e ects o drugs that interrupt microtubule unction. Recall that microtubules nucleate rom centrosomes, which consist o centrioles and other associated proteins. Microtubules are extremely dynamic during M phase; they grow and shrink during M phase at rates much greater than during other phases o the cell cycle. This increased dynamic instability during M phase allows microtubules to locate and attach to the chromosomes. Once the kinetochore o each chromosome is attached to a microtubule, microtubuleassociated proteins act as motors to align the kinetochorebound chromosomes at the equator o the cell (def ned by the midpoint between the two centrosomes). When every chromosome has aligned at the equator, the microtubules shorten, separating a diploid pair o chromosomes into each hal o the cell. Finally, cytokinesis (division o the cytoplasm) occurs, and two daughter cells are ormed. Although many other proteins are involved in the regulation o mitosis, microtubules have a critical role in the process. Disruption o microtubule unction reezes cells in M phase, leading eventually to the activation o programmed cell death (apoptosis). The f nal category o agents inhibits microtubule assembly or depolymerization, disrupting the mitotic spindle and inter ering with mitosis. For a summary o the major classes o chemotherapeutic agents, their cell cycle specif city, and major toxicities, see Table 41-2 (Chapter 41, Principles o Combination Chemotherapy). Capecitabine is approved or the treatment o metastatic colorectal cancer and as second-line therapy in metastatic breast cancer. Pemetrexed is also used in combination with cisplatin (see below) in the treatment o malignant pleural mesothelioma. To reduce toxicity to normal cells, patients treated with pemetrexed are also given olic acid and vitamin B12 supplementation. Thioguanine, azathioprine, and 6-mercaptopurine are structural analogues o purines. Thioguanine resembles guanine and can be ribosylated and phosphorylated in parallel with endogenous nucleotides. Azathioprine is a prodrug orm o 6-mercaptopurine; azathioprine reacts with sul hydryl compounds in the liver. Allopurinol is o ten used as a single agent to prevent the hyperuricemia that could result rom the destruction o cancer cells by chemotherapeutic agents (tumor lysis syndrome). The increased adenosine and 2 -deoxyadenosine have multiple e ects on purine nucleotide metabolism. In particular, 2 -deoxyadenosine irreversibly inhibits S-adenosylhomocysteine hydrolase, and the resulting increase in intracellular S-adenosylhomocysteine is toxic to lymphocytes. This action may account or the e ectiveness o pentostatin against some leukemias and lymphomas. Inhibitors o Ribonucleotide Reductase Hydroxyurea inhibits ribonucleotide reductase by scaveng- ing a tyrosyl radical at the active site o the enzyme. Hydroxyurea is approved or use in the treatment o adult sickle cell disease and certain neoplastic diseases. The mechanism o action o hydroxyurea in the treatment o sickle cell disease may or may not be related to inhibition o ribonucleotide reductase. As an alternative to this mechanism, hydroxyurea has been shown to increase the expression o the etal iso orm o hemoglobin (HbF), which inhibits the polymerization o sickle hemoglobin (HbS) and thereby decreases red blood cell sickling under conditions o hypoxia. Hydroxyurea signif cantly decreases the incidence o pain ul (vaso-occlusive) crisis in patients with sickle cell disease. The role o hydroxyurea in the treatment o sickle cell disease is discussed urther in Chapter 45, Pharmacology o Hematopoiesis and Immunomodulation. Hydroxyurea is most commonly used in the treatment o myeloproli erative disorders such as polycythemia vera and essential thrombocytosis or or palliative control o blood counts in acute myelogenous leukemia. In myeloproli erative disorders, hydroxyurea can be used as a single agent or in combination with other agents to inhibit the excessive growth o myeloid cells in the bone marrow. The applications o hydroxyurea or these indications have been limited somewhat by concerns that long-term hydroxyurea use may be leukemogenic; there ore, this may be an example o the phenomenon that certain antitumor agents can also cause cancer. These drugs are substrates or the various pathways o nucleotide metabolism, including ribosylation, ribonucleotide reduction, and nucleoside and nucleotide phosphorylation. Major adverse e ects o thioguanine include bone marrow suppression and gastrointestinal injury. The relative importance o these actions in mediating the cellular toxicity o the drug remains to be elucidated. Cladribine is approved or use in the treatment o hairy cell leukemia and has been used experimentally in the treatment o other types o leukemia and lymphoma. Cytarabine is used to induce and maintain remission in acute myelogenous leukemia; it is especially e ective or this indication when combined with an anthracycline (see below). Cytarabine has an arabinose sugar in place of ribose (note the chirality of the hydroxyl group highlighted in blue). Gemcitabine is a uorinated cytidine analogue in which the hydrogen atoms on the 2 carbon o deoxycytidine are replaced by uorine atoms. The clinical use o these agents was sparked by observations that nitrogen mustards, derivatives o wartime agents that caused dramatic suppression o hematopoietic cells, could have therapeutic utility in blood-derived malignancies such as leukemias and lymphomas. Alkylation o guanine residues can also result in cleavage o the guanine imidazole ring, abnormal base-pairing between the alkylated guanine and thymine, or depurination. Importantly, the mutations caused by these processes can increase the risk o developing new cancers. Although all nitrogen mustards are relatively reactive, the individual agents vary in the speed with which they react with nucleophiles; this act has signif cant impact on their clinical use. Highly unstable compounds, such as mechlorethamine, cannot be administered orally because such agents alkylate target molecules within seconds to minutes. Because o this high reactivity, these molecules are power ul vesicants (causing blisters) and can severely damage skin and so t tissue i they leak out o blood vessels. For example, thiotepa can be instilled into the bladder to treat superf cial bladder cancers. In contrast to mechlorethamine and thiotepa, chlorambucil and melphalan are much less reactive and can be administered orally. It is not clear whether carbamoylation contributes signif cantly to the activity o nitrosoureas. For example, nitrosoureas are use ul in the treatment o brain tumors, because their high lipid solubility enables them to cross the blood­brain barrier. Several nonclassical alkylating agents also deserve mention as clinically use ul drugs. A metabolite o procarbazine unctions as a monoamine oxidase inhibitor, and toxicity related to this activity- such as tyramine sensitivity, hypotension, and dry mouth-can occur. Temozolomide, an oral alkylating agent, is an imidazotetrazine derivative o dacarbazine. Temozolomide is widely used in the treatment o gliomas and o glioblastoma multiorme in particular. Its action is synergistic with radiation, and it enhances survival in glioblastoma when used in combination with radiotherapy or this disease. Through natural selection, tumor cells can develop resistance to a single alkylating agent as well as cross-resistance to other drugs in the same class. Highly reactive drugs can be deactivated by intracellular nucleophiles such as glutathione. Increased expression o this enzyme in neoplastic cells is associated with resistance to alkylating agents. First, toxicity typically mani ests in rapidly proli erating tissues, such as bone marrow, gastrointestinal and genitourinary tract epithelium, and hair ollicles. This results in myelosuppression, gastrointestinal distress, and alopecia (hair loss). The nitrogen o mechlorethamine per orms a nucleophilic attack on one o its own -carbons, resulting in an unstable intermediate that is highly electrophilic (not shown). The nucleophilic N-7 o guanine reacts with this unstable intermediate, resulting in an alkylated guanine. The process o alkylation can be repeated, with a second guanine acting as a nucleophile. This toxicity can be treated by using the sulfhydryl-containing molecule mesna, which is also concentrated in the urine and rapidly inactivates the acrolein. The immune response requires rapid proliferation of lymphocytes; this makes lymphocytes especially vulnerable to damage by alkylating agents. Thus, in addition to their anticancer activity, alkylating agents such as cyclophosphamide are also effective at immunosuppression. This "toxicity" has been put to clinical use: administered at doses lower than those used for antineoplastic therapy, alkylating agents are used to treat autoimmune diseases and organ rejection (see Chapter 46). One approach to limiting toxicity has been to develop alkylating agents that accumulate preferentially inside tumor cells. An example of one such agent is melphalan, or phenylalanine mustard; this agent was designed to target melanoma cells, which accumulate phenylalanine for the biosynthesis of melanin. Another example is estramustine, in which the mustard component is conjugated to estrogen; this agent was designed to target breast cancer cells that express the estrogen receptor. Interestingly, neither melphalan nor estramustine works as intended, although they both have clinical utility; through mechanisms that are still poorly understood, melphalan is active against multiple myeloma, and estramustine is used to treat prostate cancer. Cyclophosphamide is a prodrug that must be oxidized by P450 enzymes in the liver in order to become pharmacologically active. Hydroxylation converts cyclophosphamide to 4-hydroxycyclophosphamide; this active metabolite can be further oxidized to the inactive metabolite 4-ketocyclophosphamide or undergo ring cleavage to the active metabolite aldophosphamide. Aldophosphamide can be oxidized by aldehyde oxidase to the inactive metabolite carboxyphosphamide or be converted to the highly toxic metabolites acrolein and phosphoramide mustard. Accumulation of acrolein in the bladder can cause hemorrhagic cystitis; this adverse effect of cyclophosphamide can be ameliorated by co-administration of mesna, a sulfhydryl compound that inactivates the acrolein (not shown). As an antitumor agent, cisplatin is thought to act similarly to bis-alkylating agents. Cisplatin can be administered intravenously, but it can also be e ective when exposed directly to tumor cells. One example is in treating ovarian cancer, which spreads along the inner lining o the peritoneal cavity. For this application, cisplatin is in used directly into the peritoneal cavity to achieve high local concentrations o the drug while decreasing systemic toxicity. Because the dose-limiting toxicities o cisplatin, bleomycin, and etoposide di er rom one another, each o these drugs could be used at the maximum-tolerated dose (see Chapter 41). Gastrointestinal symptoms such as nausea and vomiting are also common; this is o concern because dehydration due to protracted vomiting can exacerbate cisplatin-induced kidney damage and lead to irreversible renal ailure. As with the alkylating agents, the anticancer properties o cisplatin were discovered by a chance observation. Similar compounds with trans conformations cannot effectively cross-link adjacent guanines. Thiol-containing compounds, such as amifostine, can ameliorate cisplatin nephrotoxicity without diminishing its antitumor e ects. Carboplatin, a cisplatin analogue that is less nephrotoxic, has replaced cisplatin in many chemotherapy regimens. Oxaliplatin, a third platinum compound, has activity in the treatment o colorectal cancer and other gastrointestinal malignancies. Like cisplatin, oxaliplatin causes cumulative neurotoxicity; oxaliplatin also induces a unique acute neurotoxicity that is exacerbated by exposure to cold temperatures. Bleomycin the bleomycins, a amily o natural glycopeptides synthesized by a species o Streptomyces, have prominent cytotoxic activity. Topotecan is used in the treatment o metastatic ovarian cancer, small cell lung cancer, and other neoplasms. Specif cally, this agent shows e ectiveness in treating ovarian neoplasms that are resistant to cisplatin, which are otherwise di f cult to treat e ectively. The antineoplastic camptothecins, anthracyclines, epipodophyllotoxins, and amsacrine act in this manner. Camptothecins the camptothecins are semisynthetic molecules derived rom alkaloid extracts o Camptotheca plants. Irinotecan was initially introduced or the treatment o advanced colon cancer, although it may also be e ective in treating other tumor types. Irinotecan use is limited by severe gastrointestinal toxicity, leading to potentially li e-threatening diarrhea. As with many other chemotherapeutic agents, irinotecan also causes dosedependent bone marrow suppression. Anthracyclines, natural antitumor antibiotics isolated rom a species o the ungus Streptomyces, are among the most clinically use ul cytotoxic cancer chemotherapeutic agents. Like many other antineoplastic agents, anthracyclines cause myelosuppression and alopecia.

References

• Brown BG, Bolson EL, Dodge HT: Dynamic mechanisms in human coronary stenosis, Circulation 70:917, 1984.
• Oudijk MA, Michon MM, Kleinman CS, et al: Sotolol in the treatment of fetal dysrrhythmias. Circulation 2000; 101:2721-2726.
• Debi U, Kaur R, Prasad KK, et al: Pancreatic trauma, World J Gastroenterol 19(47):9003-9011, 2013.
• Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1998;21(4):454-460.